A Phase 4 Multicenter, Open-Label, Single Arm Study to Evaluate Switching From BRACET/Gilenya® to Natalizumab in Subjects With Relapsing Forms of Multiple Sclerosis (MS)
Phase of Trial: Phase IV
Latest Information Update: 09 Jun 2017
Price : $35 *
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms ESCALATE
- Sponsors Biogen
- 08 Jan 2016 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 18 Jan 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
- 22 Sep 2014 New trial record